Profile of pacritinib and its potential in the treatment of hematologic disorders

Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinase 3 providing potential in the treatment of hematological malignancies such as myeloproliferative neoplasias, acute myeloid leukemia, and various lymphomas. Pacritinib has po...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatzimichael, Eleftheria, Tsolas, Evangelos, Briasoulis, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145824/
https://www.ncbi.nlm.nih.gov/pubmed/25170285
http://dx.doi.org/10.2147/JBM.S51253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145824/
https://www.ncbi.nlm.nih.gov/pubmed/25170285
http://dx.doi.org/10.2147/JBM.S51253

Ejemplares similares